Automate Your Wheel Strategy on VALN
With Tiblio's Option Bot, you can configure your own wheel strategy including VALN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VALN
- Rev/Share 2.0953
- Book/Share 2.1712
- PB 3.9384
- Debt/Equity 1.0563
- CurrentRatio 2.2658
- ROIC -0.1891
- MktCap 718222643.3762
- FreeCF/Share -0.4005
- PFCF -20.8852
- PE -7.1871
- Debt/Assets 0.4167
- DivYield 0
- ROE -0.5374
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | VALN | H.C. Wainwright | -- | Buy | -- | $18 | Aug. 19, 2025 |
News
Levi & Korsinsky Reminds Shareholders of an Investigation into Valneva SE (VALN) Regarding Potential Securities Fraud Allegations
Published: March 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Valneva SE ("Valneva SE") (NASDAQ:VALN) concerning possible violations of federal securities laws. On February 25, 2025, the U.S. Centers for Disease Control and Prevention ("CDC") posted a notice on its website announcing that "CDC is currently investigating five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ [Valneva's chikungunya virus vaccine] among people 65 years of age and older.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Investors to Reach Out
Published: March 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Valneva SE ("Valneva" or "the Company") (NASDAQ:VALN). Investors who purchased Valneva securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VALN.
Read More
Valneva Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older
Read More
Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023) Strong year-end cash position of €168.3 million Substantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 2025 2025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn Saint-Herblain (France), February 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its preliminary unaudited full-year 2024 revenue and cash results1 and provided a 2025 outlook. The Company will …
Read More
About Valneva SE (VALN)
- IPO Date 2021-05-05
- Website https://valneva.com
- Industry Biotechnology
- CEO Thomas Lingelbach
- Employees 713